Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Notes:
In the new clients trend, Belgium, Spain, France, Cyprus, United Kingdom and Turkey excluded because of insufficient data provision. Values for Sweden 1999, Romania 1999, Ireland 2004 and Poland 2004 estimated from percentage change between all available years as 452, 452, 2259 and 6947, respectively.
In the all clients trend, Belgium, Czech Republic, Spain, France, Latvia, Lithuania, Romania and Turkey excluded because of insufficient data provision. Values for Sweden 1999, Ireland 2004, Poland 2004 and Portugal 2004 estimated from percentage change between all available years as 1275, 5253, 12024 and 30214, respectively.
In the treatment units trend, Belgium, Spain, France, Cyprus, Latvia, Lithuania, Austria, Romania and Turkey excluded because of insufficient data provision. Values for Sweden 1999, Ireland 2004 and Poland 2004 estimated from percentage change between all available years as 33, 171 and 240, respectively.
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Sources:
2005 Reitox national reports - Standard Table 4 - First Treatments.